[Gliclazide in the non-insulin-dependent diabetic patient in geriatrics].
In the present open clinical pilot study of 12 months duration we tested the metabolic and hemato-biological efficacy as well as the clinical tolerance of the oral antidiabetic agent gliclazide, a second-generation sulfonylurea derivate, on a group of 20 hospitalized geriatric patients (mean age 80.5 +/- 10.2 years). Gliclazide was proven to be a reliable blood-sugar lowering agent with a generally good subjective tolerance. There were no undesired side-effects on the renal, hepatic and hematopoietic systems.
Frühwald
T
T
Haus der Barmherzigkeit, Wien.
Böhmer
F
F
D000284:Administration, Oral; D000368:Aged; D000369:Aged, 80 and over; D001786:Blood Glucose / Q000378:metabolism; D003924:Diabetes Mellitus, Type 2 / Q000628:therapy*; D005260:Female; D005907:Gliclazide / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D010865:Pilot Projects; D013453:Sulfonylurea Compounds / Q000627:therapeutic use*
D001786:Blood Glucose; D013453:Sulfonylurea Compounds; D005907:Gliclazide
Gliclazid beim nichtinsulinpflichtigen Diabetiker in der Geriatrie.